Published 11/06/2009 by World Pharma News
Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
The CONTACT study will assess as primary endpoints the potential...
Share this
What others report on the same story